Kura Oncology, Inc. (NASDAQ: KURA)

Kura Oncology, Inc. is a biopharmaceutical company focused on developing precision medicines for cancer treatment.

The company discovers and develops small molecule inhibitors that target dysregulated signaling pathways in oncology and hematology.

Its lead product KOMZIFTI (ziftomenib) received FDA approval in November 2025 for adult patients with relapsed or refractory NPM1 mutated AML who lack satisfactory alternative treatments.

Beyond KOMZIFTI the pipeline includes darlifarnib a farnesyl transferase inhibitor being evaluated in combination with targeted therapies for solid tumors and next generation menin inhibitors such as KO-7246 for diabetes cardiometabolic disorders and additional oncology indications.

The company generates revenue primarily from sales of its approved product KOMZIFTI in the United States.

Under its collaboration with Kyowa Kirin Kura Oncology records US sales and shares profits and losses equally with the partner.

Additional revenue comes from upfront payments milestone payments and profit sharing under the Kyowa License Agreement and other collaborative arrangements.

The company may also earn royalties on future product sales outside the United States as part of its licensing deals.

Kura Oncology occupies a niche in the menin inhibitor space as the first company to secure FDA approval for a menin inhibitor for once daily oral administration.

This positions KOMZIFTI ahead of competitors such as Syndax Janssen Servier and Biomea Fusion which are developing menin inhibitors but have not yet received approval.

The product’s once daily dosing lack of a QT interval black box warning and compatibility with strong CYP3A4 modulators provide differentiated advantages over rival molecules.

In the farnesyl transferase inhibitor arena the company advances darlifarnib which has shown promising activity in combination regimens for renal cell carcinoma non small cell lung cancer colorectal cancer and pancreatic ductal adenocarcinoma.

These efforts place Kura Oncology among a select group of biotechs pursuing combination strategies to overcome resistance mechanisms in solid tumors.

Kura Oncology serves healthcare providers including hospitals oncology clinics and specialty pharmacies that treat patients with acute myeloid leukemia and solid tumor indications.

The company works with specialty distributors and payor organizations to secure coverage and reimbursement for KOMZIFTI.

Collaborations with partners such as Kyowa Kirin and Mirati expand its reach to additional clinical sites and patient populations.